Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Allogene Therapeutics, Inc. ALLO

Set alert

Price alert · ALLO

All alert types
1.11 USD +0.02 +1.83%

As of Nov 3, 2:03 PM ET

Bid
1.11 × 229
Ask
1.12 × 290
1.10 Day range 1.14
1.04 52-week range 4.46
YTD
-18.98%
1 year
-5.93%
Open
1.12
Prev close
1.09
Mkt cap
385.78M
Vol
13.35M
Avg vol
5.99M
EPS
-0.66
P/E
0.00
Div yield
0.00%
More statistics
Low
1.10
High
1.14
Forward P/E
-1.50
Beta
0.84
Short ratio
11.46
Inst. own
80.20%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
2.47
200-d avg
2.83
1y target
9.04

6M chart

Chart tools
Interval
1m5m15m30m

Signals (29)
NameDateAgo
MACD: Sell SignalNov 2, 20261 day ago
RSI: OversoldOct 30, 20264 days ago
MACD: Buy SignalOct 27, 20261 week ago
MACD: Sell SignalOct 26, 20261 week ago
RSI: OversoldOct 22, 20261 week ago
MACD: Buy SignalOct 21, 20261 week ago
RSI: OversoldOct 1, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
SMA: BearishAug 26, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BearishAug 20, 20262 months ago
SMA: BullishAug 19, 20262 months ago
SMA: BullishAug 6, 20262 months ago
MACD: Buy SignalJul 30, 20263 months ago
MACD: Sell SignalJul 13, 20263 months ago
SMA: BearishJul 10, 20263 months ago
SMA: BearishJul 2, 20264 months ago
SMA: BullishJul 1, 20264 months ago
SMA: BearishJun 30, 20264 months ago
SMA: BearishJun 30, 20264 months ago

Newest 20 of 29.

Analyst view

Consensus: buy

Buy
Price target (mean) 9.04 +714.6% upside
Target (low)
3.00
Target (mean)
9.04
Target (high)
14.00
Ratings (0m) 18 13 buy · 5 hold · 0 sell
  • Strong buy4
  • Buy9
  • Hold5
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 18
  • 1 month ago 18
  • 2 months ago 17
  • 3 months ago 17

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ALLO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.32709-0.41 – -0.28-0.51+35.9%12.11K-42.3%11
Next quarter-0.3475-0.43 – -0.29-0.38+8.6%4.17K-81.0%9
Current year-1.31-1.38 – -1.17-2.09+37.1%31.37K-67.0%10
Next year-1.38-1.71 – -1.23-1.31-5.1%47.18K+50.4%15

Upgrades and downgrades

The latest rating changes

ALLO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024Piper SandlerMaintainedOverweightOverweight
Nov 8, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 30, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 9, 2024CitigroupMaintainedBuyBuy
Aug 9, 2024Truist SecuritiesReiteratedBuyBuy
Aug 8, 2024Canaccord GenuityMaintainedBuyBuy
May 31, 2024Piper SandlerInitiated—Overweight
May 21, 2024OppenheimerMaintainedOutperformOutperform
May 16, 2024HC Wainwright & Co.MaintainedBuyBuy
May 15, 2024Truist SecuritiesMaintainedBuyBuy
May 14, 2024StifelMaintainedHoldHold
Mar 19, 2024HC Wainwright & Co.ReiteratedBuyBuy
Mar 15, 2024RBC CapitalReiteratedOutperformOutperform
Feb 27, 2024JP MorganMaintainedOverweightOverweight
Jan 19, 2024HC Wainwright & Co.MaintainedBuyBuy
Jan 5, 2024GuggenheimDowngradeBuyNeutral
Jan 5, 2024JMP SecuritiesDowngradeMarket OutperformMarket Perform
Dec 8, 2023CitigroupInitiated—Buy
Nov 15, 2023HC Wainwright & Co.MaintainedBuyBuy
Sep 25, 2023JP MorganMaintainedOverweightOverweight
Aug 7, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 3, 2023OppenheimerReiteratedOutperformOutperform
Aug 3, 2023EF HuttonReiteratedBuyBuy
Jul 12, 2023Truist SecuritiesMaintainedBuyBuy
Jun 20, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jun 16, 2023Canaccord GenuityReiteratedBuyBuy
Jun 5, 2023JMP SecuritiesReiterated—Market Outperform
Jun 5, 2023EF HuttonReiteratedBuyBuy
May 26, 2023EF HuttonReiteratedBuyBuy